Filana Therapeutics (FLNA) Assets Average (2011 - 2026)

Filana Therapeutics has reported Assets Average for 16 years, with the latest figure at $106.1 million in Q2 2026.

• On a quarterly basis, Assets Average fell 23.18% year-over-year to $106.1 million in Q2 2026; TTM through Jun 2026 was $106.1 million, a 23.18% decrease from a year earlier, with the FY2025 full-year figure at $137.9 million, down 10.77% from the prior year.
• Assets Average was $106.1 million for Q2 2026 at Filana Therapeutics, down from $113.4 million in the prior quarter.
• The five-year high for Assets Average was $255.5 million in Q1 2022, with the low at $106.1 million in Q2 2026.
• Average Assets Average over 5 years is $180.7 million, with a median of $187.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Assets Average soared 35.05% in 2022, then tumbled 43.27% in 2025.
• Over 5 years, Assets Average stood at $221.1 million in 2022, then retreated by 26.67% to $162.1 million in 2023, then grew by 17.61% to $190.6 million in 2024, then slumped by 34.93% to $124.0 million in 2025, then fell by 14.44% to $106.1 million in 2026.
• The last three Assets Average figures came in at $106.1 million (Q2 2026), $113.4 million (Q1 2026), and $124.0 million (Q4 2025), per Business Quant data.